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ABSTRACT 
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alcohol dehydrogenase at tryptophan-110 on enantioselectivity of 
reduction of phenyl–ring-containing ketones 
Major Field : Chemistry 
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The asymmetric reduction of selected phenyl-ring-containing ketones by various mutants 
of Thermoanaerobacter ethanolicus secondary alcohol dehydrogenase (TeSADH) was 
studied using single and dual site mutagenesis. The expansion of both small and large 
pockets of TeSADH in the mutant W110A/I86A not only accommodates the substrates of 
single mutants W110A and I86A within the active site, but also expands the substrate 
scope to ketones bearing two sterically demanding groups (bulky-bulky ketones); which 
are not substrates for TeSADH single mutants. We also explored the regio- and 
enantioselective reduction of diketones using W110A/I86A TeSADH. The double mutant 
exhibited dual stereopreferences that resulted in Prelog products and the anti-Prelog 
products were occasionally observed. Kinetic parameters, Michaelis-Menten constant 
(Km) and maximum velocity (Vmax), for the reduction reactions of substituted 4-phenyl-2-
butanone and 1-phenyl-2-propanone were consistent with that of the enantioselectivity 
values. Moreover, we conducted asymmetric reduction of substituted 2-tetralones, using 
various mutants of TeSADH which revealed that the stereoselectivity and its magnitude 
were dependent on the position of substituent on the aromatic ring; such an outcome has 
been attributed due to different binding modes of these substrates in the enzyme active 
site. In addition, changing the position of the substituent on the aromatic ring also has a 
xiv 
 
great impact on the binding affinity and maximum catalytic rate, as reflected by the 
kinetic parameters Vmax and Km. 
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 ﻣﻠﺨﺺ اﻟﺮﺳﺎﻟﺔ
 
 
 :ﻋﺪي ﻓﻼح  ﺑﺸﺎراتاﻻﺳﻢ اﻟﻜﺎﻣﻞ
 
ﻋﻠﻰ اﻻﺧﺘﺰال ﻏﯿﺮ اﻟﻤﺘﻤﺎﺛﻞ  011prTﻋﻠﻰ ﻣﻮﻗﻊ  HDASeT( )ﻣﺨﺘﻠﻔﺔ ﻣﻦ اﻻﻧﺰﯾﻢ ﺗﺎﺛﯿﺮ طﻔﺮات   ﻋﻨﻮان اﻟﺮﺳﺎﻟﺔ:
 ﻟﻤﺮﻛﺒﺎت اﻟﻜﯿﺘﻮن اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ ﺣﻠﻘﺔ اروﻣﺎﺗﯿﺔ 
 
 اﻟﺘﺨﺼﺺ: ﻛﯿﻤﯿﺎء
 
 6102:ﺗﺎرﯾﺦ اﻟﺪرﺟﺔ اﻟﻌﻠﻤﯿﺔ
 
ﺗﻢ ﺗﺤﻀﯿﺮ ﻣﺮﻛﺒﺎت اﻟﻜﺤﻮل ﻣﻦ اﻻﺧﺘﺰال ﻏﯿﺮ اﻟﻤﺘﻤﺎﺛﻞ ﻟﻤﺠﻤﻮﻋﺔ ﻣﻦ ﻣﺮﻛﺒﺎت اﻟﻜﯿﺘﻮن اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ ﺣﻠﻘﺔ 
. ﺑﺎﺳﺘﺨﺪام اﻟﻄﻔﺮة اﻟﺜﻨﺎﺋﯿﺔ ﻟﻠﻤﻮﻗﻊ اﻟﻨﺸﻂ ﻟﻼﻧﺰﯾﻢ ﺗﻤﻜﻨﺎ ﻣﻦ )HDASeT( اروﻣﺎﺗﯿﺔ ﺑﺎﺳﺘﺨﺪام طﻔﺮات ﻣﺨﺘﻠﻔﺔ ﻣﻦ اﻻﻧﺰﯾﻢ 
اﻟﺘﻲ ﯾﻤﻜﻦ اﺧﺘﺰاﻟﮭﺎ ﺑﺎﻟﻄﻔﺮة اﻻﺣﺎدﯾﺔ وﻛﺬﻟﻚ ﺗﻤﻜﻦ ﻣﻦ زﯾﺎدة ﻋﺪد ﻣﺮﻛﺒﺎت اﻟﻜﯿﺘﻮن اﻟﺘﻲ اﺧﺘﺰال ﺟﻤﯿﻊ ﻣﺮﻛﺒﺎت ﻛﯿﺘﻮن 
ﯾﻤﻜﻦ ان ﺗﺨﺘﺰل ﺑﻮاﺳﻄﺔ اﻻﻧﺰﯾﻢ وﺧﺼﻮﺻﺎ ﻣﺮﻛﺒﺎت اﻟﻜﯿﺘﻮن اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ ﻣﺠﻤﻮﻋﺎت اروﻣﺎﺗﯿﺔ ﺣﻮل اﻟﻜﺎرﺑﻮﻧﯿﻞ. 
ﻟﯿﺔ. ﺗﻢ ﻗﯿﺎس اﻟﻤﻌﺎﻣﻼت ﻛﺬﻟﻚ ﺗﻤﻜﻨﺎ ﻣﻦ اﺧﺘﺰال ﻣﺮﻛﺒﺎت ﻛﯿﺘﻮن اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ ﻣﺠﻤﻮﻋﺘﯿﻦ ﻛﺎرﺑﻮﻧﯿﻞ ﺑﻔﻌﺎﻟﯿﺔ ﻋﺎ
( eeﻣﻊ ﻗﯿﻢ ) ﺔﺑﺮوﺑﺎﻧﻮن وﻛﺎﻧﺖ ﻣﺘﻮاﻓﻘ -٢ -ﻓﯿﻨﯿﻞ -١ﺑﯿﻮﺗﺎﻧﻮن و - ٢-ﻓﯿﻨﯿﻞ -٤( ﻟﻤﺮﻛﺒﺎت Vxam  dnaKmاﻟﺤﺮﻛﯿﺔ )
( وﻣﺸﺘﻘﺎﺗﮭﺎ ووﺟﺪﻧﺎ ان senolartet-2اﻟﺘﻲ ﺗﻢ اﯾﺠﺎدھﺎ. ﺑﺎﻻﺿﺎﻓﺔ اﻟﻰ ذﻟﻚ ﺗﻢ اﺟﺮاء اﺧﺘﺰال ﻏﯿﺮ ﻣﺘﻤﺎﺛﻞ ﻟﻤﺮﻛﺒﺎت )
 ﻋﻠﻰ ﻧﻮع اﻟﻜﺤﻮل اﻟﻨﺎﺗﺞ وﺗﻢ ﻗﯿﺎس ﻣﻌﺎﻣﻼت اﻟﺤﺮﻛﯿﺔ ﻋﻠﻰ اﻟﺤﻠﻘﺔ اﻻروﻣﺎﺗﯿﺔاﻟﺘﻔﺮع  ھﻨﺎك ﺗﺎﺛﯿﺮ ﻛﺒﯿﺮ ﻟﻤﻮﻗﻊ ﻣﺠﻤﻮﻋﺔ
 .(  ﻟﮭﺬه اﻟﻤﺮﻛﺒﺎتVxam  dnaKm)
 .
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1 CHAPTER 1 
2 INTRODUCTION AND LITERATURE REVIEW 
1.1 Background 
 
Optically active alcohols are very important synthons in the pharmaceutical, 
agrochemical, food, and petroleum industries. They are generally produced in industry 
from their racemates via kinetic resolution (KR), where two enantiomers react with 
different reaction rates in a chemical reaction, resulting in an enantioenriched alcohol. 
However, this approach has a drawback of being limited to a maximum yield of 50% 
pure enantiomeric product [1, 2]. Deracemization of racemic alcohols is an attractive 
approach for the production of optically active alcohols in 100% theoretical yield [3, 4], 
and thus considered as a potential alternative to KR. However, all reported 
deracemization approaches require two compatible reaction systems to work in one pot, 
which makes searching for new deracemization methods a challenge. Another approach 
for producing optically active alcohols is asymmetric reduction of their corresponding 
ketones. This can be done chemically or using biocatalysis; however, the use of 
biocatalysis is preferred for several reasons. First, enzymes have high regio-, chemo-, and 
steroselectivity. Second, their application in fine chemical industry has been spreading 
very fast because it cures industrial challenges such as cost-effectiveness and 
sustainability .Third, enzymes are environmentally benign since they are natural catalysts 
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and they work under mild conditions, which reduce side effects like epimerization and 
isomerization [5].  
Asymmetric reduction of pro-chiral ketones that contain bulky groups on both 
sides of the carbonyl, like 2-tetralone and its phenyl-substituted analogs, is of great 
interest because most of the reported methods for their asymmetric reduction are either 
poorly stereoselective or non-stereoselective [6]. This calls for methods that can reduce 
such compounds with high enantioselectivities. One important class of reactions is 
biocatalytic asymmetric reduction catalyzed by (ADHs) in which nicotinamide-adenine 
dinucleotide (NADH) or its phosphate (NADPH) act as hydride sources (Figure 1). 
Commercially available ADHs have been employed efficaciously in asymmetric redox 
reactions. For example, yeast ADH (YADH), horse liver ADH (HLADH), 
Thermoanaerobium brockii ADH (TbADH) [7] and Thermoanaerobacter ethanolicus 
secondary ADH (TeSADH) [8] have been employed in the enantioselective reduction and 
enantiospecific  oxidation of aromatic ketones and alcohols, respectively [9].  
 
 
 
Figure 1: The asymmetric reduction of prochiral ketones catalyzed by alcohol  
dehydrogenases (ADHs). R1 has higher Cahn-Ingold-Prelog priority than R2.    
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Although these reactions are enantioselective and lead to optically active alcohols 
with high enantiomeric excess (ee), the high substrate specificity of ADHs is still a major 
challenge that is restricting their use in organic synthesis. Herein, we propose the use of 
various mutants of TeSADH in the asymmetric reduction of 2-tetralone derivatives and 
other phenyl ring containing ketones shown in Figure 2.  
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Figure 2: Different substrates studied with various mutants of TeSADH. 
 
 
1.2 Alcohol Dehydrogenases 
         Alcohol dehydrogenases (ADHs, EC 1.1.1.X, X = 1 or 2) catalyze the reversible 
asymmetric reduction of ketones and aldehydes to their corresponding alcohols. In living 
organisms, these reactions require co-enzymes, usually NADPH or NADH, which act as 
hydride sources for reduction and their corresponding oxidized forms (NADP+ or NAD+) 
are used for oxidation reactions. Moreover, enantiomerically pure alcohols are important 
building blocks for agricultural and bioactive pharmaceuticals [10].  
TeSADH is an important ADH, which has been successfully employed in the 
reversible asymmetric reduction of ketones. This enzyme has gained significant interest 
because of its high thermal stability and tolerance to various organic solvents [11]. The 
active site of TbADH is identical to the active site of TeSADH proposed by Keinan that 
[12], consists of two pockets, one large and one small; the smaller pocket possesses a 
higher affinity for alkyl chains than the large pocket, although it cannot accommodate 
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sterically bulkies groups than isopropyl [13]. The crystal structure of TbADH was 
discovered in 1998 [14], which provided a better understanding of the active site 
architecture and enabled the design of useful mutants of TeSADH. An interesting site for 
mutations turned to be Trp-110, which forms part of the large pocket, as shown in Figure 
3 [15].  Musa et al. has earlier reported that the W110A mutation alters the substrate 
specificity of TeSADH to accommodate phenyl-ring-containing alcohols and their 
corresponding ketones in agreement with Prelog’s rule [16].On the other hand substrate 
specificity for ADHs depends on the nature of the aryl/alkyl group attached to alpha 
carbon of the secondary alcohol or their corresponding ketones. In  attempt  to expand its 
substrate specificity, several mutants of TeSADH were designed  and revealed to 
recognize sterically-hindered groups such as phenyl rings or long alkyl chains, that are 
not  recognize by wild-type TeSADH. Among them W110G, W110A, W110V, and 
W110A/I86ATeSADH, which used in this study. 
.  
Figure 3: The structure of the active site of TeSADH and TbADH (Protein Eng. Des. 
2007, 20, 47-55). 
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1.3. ADH-Catalyzed Asymmetric redox reactions 
        Asymmetric reduction of ketones involves the addition of two hydrogen atoms to a 
carbonyl group that results in forming an optically active alcohol. In ADH-catalyzed 
reduction of ketones, the pro-R or pro-S hydride of the NAD(P)H is delivered either from 
the Re face or Si face of a prochiral ketone, leading to formation of corresponding alcohol 
with S or R configuration, respectively, if the larger group (R2) has higher Cahn-Ingold-
Prelog priority than the smaller group (R1), The pro-R hydride NAD(P)H is delivered  
from the Re face to produce the corresponding S in most the cases [17]. Such a 
stereochemical outcome is referred to Prelog’s rule. For example, yeast ADH, horse liver 
ADH, TbADH and TeSADH are considered as Prelog ADHs. Whereas, Lactobacillus 
kefir ADH is known as an anti-Prelog ADHs, a rare type of ADHs. The stereochemistry 
of hydride addition in ADH-catalyzed reduction of ketones is depicted in Figure 4. 
 
 
Figure 4: The stereochemistry of hydride addition in ADH-catalyzed reduction of 
ketones.  ADPR = adenosine diphosphoribose. R2 has higher Cahn-Ingold-Prelog priority 
than R1. 
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TeSADH is known to be an effective biocatalyst for various synthetic applications 
[18] owing to the fact that it accepts alcohols and their corresponding ketones as 
substrates with high activities and stereoselectivities. In addition it withstands 
denaturation in high concentrations of organic solvents [19], which, in turn, allow it the 
use of cosubstrates like acetone and 2-propanol in the oxidation and reduction pathways, 
respectively, in a reasonable concentrations for the regeneration of coenzyme, to makes 
the process catalytic (Figure 5), Moreover, TeSADH is thermally stable.  
 
Figure 5: Regeneration of coenzyme in TeSADH-catalyzed transformations. R1 has 
higher Cahn-Ingold-Prelog priority than R2. 
 
1.4 Asymmetric synthesis of methoxy and chloro substituted 2-tetralols and various 
phenyl ring containing ketones 
             Many bioactive compounds and heterocyclics, such as prostaglandin, dyes, 
steroids, and pharmaceuticals contain tetrahydronaphthalene core as a building block 
[20]. Methoxy substituted tetralols have been reported to possess various degrees of 
biological importance in terms of inhibition of tubulin assembly [21]. Moreover, 
enantiomerically pure (S)-2-tetralol and its hydroxy and alkoxy derivatives served as 
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intermediate  the synthesis of 2-aminotetralins, which are known to possess activity 
toward dopamine and serotonin receptors. In addition, they have been used in the 
synthesis of drugs used for the treatment of many central nervous system related 
disorders [22].  6-Chloro-2-tetralol serve as building block for chiral potassium channel 
blocker drug candidate MK-0499 (Figure 6), which can be ultimately used for the 
treatment of ventricular arrhythmias and mediates polarization of cardiac tissues [23]. 
Furthermore, it has also been used as achiral substrate in the total synthesis of anti-
myocardial ischemia in drug [24]. On the other hand, (S)-4-(4-Hydroxyphenyl)-2-
butanol, commercially known as (S)-rhododendrol, finds several pharmaceutical 
applications including as hepato-protective [25]. Moreover, rhododendrol and its 
glucoside have been used   in skin-lightening cosmetics and as a melanin-inhibitor [26]. 
4-Pheny-2-butanone constitutes a precursor for the synthesis of antihypertensive agents 
such as bufeniode or labetalol [27], which use to treat high blood pressure, and 
spasmolytics or antileptics, such as emepronium bromide [28]. Also, protease inhibitors 
for the treatment of acquired immunodeficiency syndrome (AIDS) such as VX-478 and 
SC-52151 involve 4-phenyl-2-butanol moiety (Figure 7) [29]. Enantiomerically pure α-
hydroxy carbonyl compounds are important synthons in the asymmetric synthesis of 
natural products. Consequently, efficient methods for the construction of 
enantiomerically pure, or enriched, α-hydroxy carbonyl derivatives are in demand [30]. 
Moreover, optically pure 1, 2-diarylethanols are pharmaceutically interesting due to their 
applications in  anti-cancer combretastatin (Figure 8) [31].  
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Figure 6: The pharmacological importance of tetrahydronaphthalene moiety.in various 
bioactive pharmscuticals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
 
                                      4-phenyl-2-butanol as a bulding block in the Labetalol  
 
 
Figure 7: 4-phenyl-2-butanol scaffold containing important bioactive pharmacuticals. 
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Figure 8: optically pure 1, 2-diarylethanols scaffold containing important bioactive 
pharmacuticals. 
 
several synthetic methods for the asymmetric synthesis of substituted 2-tetraloles 
have been reported. Mogi et al. reported the asymmetric transfer hydrogenation of 
substituted 2-tetralone by [RuCl2 (p-cymene)]2 complex with (R,R)-N-(2-amino-1,2-
diphenylethyl)-p-toluenesulfonamide or (1S,2R)-(_)-cis-1-amino-2-indanol (Figure 9) 
[32]. Likewise methoxy tetralones were also reduced to their corresponding (R)-
configured alcohols.  These reduction reactions resulted in moderate conversions (74-
81%) and moderate enantioselectivities (78-88% ee), as shown in Table 1. 
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Figure 9: The asymmetric reduction of substituted methoxy of 2-tetralone using 
[RuCl2(p-cymene)]2 and (R,R)-N-(2-amino-1,2-diphenylethyl)-p-toluenesulfonamide or 
(1S,2R)-(_)-cis-1-amino-2-indanol. 
 
Table 1: The asymmetric reduction of 2-tetralone and its phenyl-ring-substituted analogs 
by transfer hydrogenation (as shown in Figure 9).  
R Ligand Yield (%) ee (%) 
H 1 81 78 
5-OMe 1 80 82 
6-OMe 1 85 83 
7-OMe 1 81 78 
8-OMe 1 74 92 
H 2 87 78 
5-OMe 2 82 77 
6-OMe 2 83 80 
7-OMe 2 81 74 
8-OMe 2 80 96 
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On the other hand, the asymmetric reduction of 2-tetralone, 5-methoxy-2-
tetralone, 7-methoxy-2-tetralone, and 8-methoxy-2-tetralone by whole cells of the fungus 
Fusarium culmorum was achieved using, which led to the formation of the corresponding 
(S)-alcohols with high conversion and moderate enantiomeric excess, (Figure 10) [33]. 
 
Figure 10: The asymmetric reduction of 2-tetralone and its methoxy substituted 
analogues by Fusarium culmorum. 
 
        Daucus carota and yeast cells were also used  of asymmetric reduction of 2-
tetralones was done by using [34]. These reactions produced the corresposning (R)-
configured alcohols in moderate enantioselectivity (70–80% ee) and poor conversion 
(50–60%) with the long incubation periods (Figure 11).  
 
Figure 11: The asymmetric reduction of 2-tetralones by using Daucus carota and yeast 
cells.   
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       In another attempt Asymmetric reduction of 2-tetralone accomplished by 
Kluyveromyces marxianus CBS 6556 yeast cells to produce (S)-2-tetralol quantitatively 
in 76% ee (Figure 12) [35]. 
 
 
Figure 12: The asymmetric reduction of 2-tetralone by Kluyveromyces marxianus CBS 
6556 yeast cells. 
  
In another report the asymmetric reduction of 2-tetralone and its methoxy and 
hydroxyl derivatives was carried out by tetrahydroxy naphthalene reductase (T4HNR) and 
T3HNR [36]. Whereas T4HNR-catalyzed reduction of 2-tetralone to (S)-2-tetralol with 
61% ee and 99% conversion, the ee and conversion of substituted 2-tetrlones turned to be 
high, as shown in (Figure 13) and Table 2. Surprisingly, the asymmetric reduction of 5-
methoxy-2-teralone by this method resulted in the corresponding R alcohol. Docking 
studies of this substrate within the active site of T4HNR showed that the inverse fit of this 
substrate , which is due to the hydrophobic interactions between the methyl of the 
methoxy group and leu-232 and Ile-274 moieties resides within the active site of T3HNR/ 
T4HNR. A comparative study T4HNR and T3HNR in the asymmetric reduction of 2-
tetralone, 5-mehtoxy-2-tetralone, and 7-mehtoxy-2-tetralone revealed enhancement in the 
ee of 5-mehtoxy-2-tetralone when T4HNR was used as a biocatalyst Table 3 [37]. 
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Figure 13: The asymmetric reduction of 2-tetralone and its methoxy and derivatives by 
tetrahydroxy naphthalene reductase (T4HNR). 
 
Table 2: The asymmetric reduction of 2-tetralone and its methoxy and hydroxyl 
derivatives by tetrahydroxy naphthalene reductase (T4HNR). 
 
substrate ee conversion configuration 
2-tetralone 61 99 S 
5-methoxy-2-tetralone 99 99 R 
7-methoxy-2-tetralone > 99 99 S 
8-methoxy-2-tetralone 99 99 S 
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Table 3 :  Reduction of 2-tetralone (1), 5-methoxy-2-tetralone (2), and 7-methoxy-2-
tetralone (3) by T3HNR/ T4HNR. 
 
 
Enzyme Substrate Yield (%) ee (%) Configuration 
T3HNR 1 66 60 S 
T3HNR 2 71 75 R 
T3HNR 3 67 > 99 S 
T4HNR 1 77 61 S 
T4HNR 2 57 99 R 
T4HNR 3 71 > 99 S 
 
In their findings, Musa et al. has reported the enantioselective reduction of phenylacetone 
by W110A TeSADH to produce (S)-1-phenyl-2-propanol in only 37% ee. However, 
W110A TeSADH-catalyzed reduction of 1-(4’-methoxyphenyl)-2-propanone resulted in 
the corresponding (S)-configured alcohol in > 99% ee (figure 14) and 2-tetralone results 
in (S)-2-tetralol in 71% ee.  
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The significant improvement in the enantioselectivity that due to the presence of methoxy 
group in phenylacetone (Figure 14) encouraged us to study the asymmetric reduction of 
substituted tetralones in asymmetric way in order to know the effect of substituents on the 
enantioselectivity of the reduction reaction. 
 
 
Figure 14: The asymmetric reduction of phenylacetone and 4-(4’-methoxyphenyl)-2-
propanone using W110A TeSADH 
 
 Some prochiral phenyl ring containing ketones which were reduced using 
W110A TeSADH to produce their corresponding (S)-configured alcohols [19]. With the 
exception of phenylacetone, which was reduced with poor enantioselectivity, all other 
tested ketones were reduced with high enantioselectivities and good yields (Table 4). 
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Table 4: Enantioselective reduction of phenyl-ring-containing ketones using W110A 
TeSADH. 
 
R Conv. (%) ee (%) 
PhCH2CH2 99 > 99 
Ph(C=O)CH2 98 > 99 
(E)-Ph-HC=CH 64 > 99 
p-MeOC6H4(CH2)2 87 91 
PhOCH2 > 99 > 99 
PhCH2 95 37 
p-MeOC6H4CH2 97 > 99 
 
            There are fewer reports on the asymmetric reduction of 1-(2-
chlorophenyl)acetone using biocatalysis. Including the use of several types of ADH table 
5 [38].  
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Table 5:  Asymmetric reduction of 1-(2-chlorophenyl)acetone by ADH 
 
ADH Conversion (%) ee (%) Configuration 
LP 20 > 99 R 
CP 97 > 99 S 
PR2 15 84 R 
A 99 > 99 S 
 
Although ADHs are versatile biocatalysts catalyzing a wide range of phenyl ring 
containing ketones, the enantioselective reduction of diaryl ketones (bulky-bulky 
ketones) or aryl- alkyl with sterically bulky alkyl groups such as propyl or phenyl ring 
containing ketones possessing two adjacent carbonyl groups, and the reduction of phenyl 
ring containing ketones  in the anti-Prelog fashion still represents a significant challenge 
in both the enzymatic and chemical reductions of ketones, The highly stereoselective 
deduction by ADHs is preferred when ketone bears one small and a bulky groups, 
Moreover, the smaller group is limited to a sterically nondemanding group such as 
methyl, ethyl, or chloromethyl [38]. Only few methods have been reported for the 
biocatalytic asymmetric reduction of ketones that bear two bulky groups (bulky–bulky 
ketones) by using (fermenting) whole cells [39] or purified enzymes[ 40].  Moreover, 
very few ADHs have shown anti-Prelog stereopreference [41, 38]. 
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 Therefore, our study focuses on we report the asymmetric bioreduction of 
various phenyl ring containing ketones by using different mutants of TeSADH. The 
specific aim of this research endeavor was to expand the biocatalyst substrate specificity, 
as well its chemo, –regio, and enantioselectivities related to the molecular structure and 
to compare the effect of different mutants on enantioselectivity and steroselectivity. The 
kinetic parameters of these reactions are also reported.  
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3  CHAPTER 2 
OBJECTIVES AND WORK PLAN 
        The main objective of this proposed study was to synthesize optically active 
substituted 2-tetralols and other phenyl-ring-containing ketones, important building 
blocks in pharmaceutical industries, from their corresponding ketones using TeSADH 
mutants. These ketones included in this study were 2-tetralone, 6-chloro-2-tetralone, 5-
methoxy-2-tetralone, 7-methoxy-2-tetralone, 8-methoxy-2-tetralone, and other phenyl-
ring-containing ketones like as 4-phenyl-2-butanone, 4-(4-methoxyphenyl)-2-butanone, 
4-phenyl-3-butyn-2-one, 1-(2-chlorophenyl)acetone, 1-(4-chlorophenyl)acetone and  1,2-
diphenylethanone. 
               W110V, W110A, W110G and W110A/I86A mutants of TeSADH were used as 
catalysts for this study. One of the major purposes of this study was to expand the 
substrate specificity of TeSADH by screening substrates that were never been used with 
this enzyme. The enzyme kinetics for these transformations were conducted to check the 
enzyme’s efficiency towards the proposed substrates and to compare the resultants 
parameters (Km and kcat), with the reported substrates such as 4-phenyl-2-butanone and 
phenylacetone with W110A TeSADH,  
The objectives of the main our study was to: 
i. Expand the substrate specificity of TeSADH. 
22 
 
ii. Employ W110G, W110A, W110V, W110A/I86A mutants in the asymmetric 
reduction of different phenyl ring prochiral ketones containing and to compare the 
percent conversion and enantiomeric excess for their reaction products.  
iii. Purify the optically active alcohols products when needed. 
iv. Characterize the chemical identity of the reaction products by IR, 1H and 13C 
NMR, and GC-MS. 
v. Characterize the stereochemical outcome of alcohols products by GC chiral 
column and polarimetry.  
vi. Study enzyme kinetics for W110A and W110G TeSADH-catalyzed reduction of 
phenyl ring prochiral ketones containing.  
 
 
 
 
 
23 
 
4 Chapter 3 
5 Experimental 
6 3.1 General 
7             Capillary gas chromatographic (GC) measurements were performed on a GC 
equipped with a flame ionization detector and an HP chiral-20B column (30 m, 0.32 
mm [i.d.], 0.25 μm film thickness) using He as the carrier gas. High pressure liquid 
chromatographic (HPLC) measurements were performed on a HPLC on a Chiralcel 
OD–H column (Daicel).  Nuclear Magnetic Resonance (NMR) spectra were recorded 
on a 500 MHz spectrometer at 500 MHz (1H) and at 125 MHz (13C) at room 
temperature in CDCl3 using the solvent peak as an internal standard. Enzyme assays 
to determine the enzyme kinetics were carried out using a Cary 100 UV-Vis 
spectrometer equipped with a temperature control from Agilent technology. 
Commercial grade solvents were used without further purification. NADPH, NADP+, 
dithiothreitol (DTT), ZnCl2, 2-tetralone (1a), 5-methoxy-2-tetralone (1b), 7-methoxy-
2-tetralone (1c), 8-methoxy-2-tetralone (1d), 6-chloro-2-tetralone (1e), 4-phenyl-2-
butanone (1f), 4-(4-methoxyphenyl)-2-butanone (1g), 4-(4-hydoxyphenyl)-2-
butanone (1h), 4-phenyl-3-buten-2-one (1i), 4-phenyl-3-butyn-2-one (1j), 1-
phenylpropane-2-one (1k), 1-(2-chlorophenyl)propan-2-one (1l), 1-(3-
(trifluoromethyl)phenyl)propan-2-one (1m), 1-phenyl-2-butanone (1n), 1-phenyl-2-
pentanone (1o), 1-phenylethannone (1p), 1,2-diphenylethanone (1q), 1,3-diphenyl-2-
propen-1-one (1r), 1-phenylpropane-1,2-dione (1s), 1-phenylbutane-1,3-dione (1u), 
4,4,4-trifluoro-1-phenylbutane-1,3-dione (1v), (rac)-1-phenylpropane-2-ol [(rac)-2k], 
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(rac)-1-phenylethanol [(rac)-2p], and (rac)-1,3-diphenyl-2-propan-1-ol [(rac)-2r]  
were used as purchased from commercial sources. (rac)-2-Tetralol [(rac)-2a], (rac)-
5-methoxy-2-tetralol [(rac)-2b], (rac)-7-methoxy-2-tetralol [(rac)-2c], (rac)-8-
methoxy-2-tetralol [(rac)-2d], (rac)-6-chloro-2-tetralol [(rac)-2e], (rac)-4-phenyl-2-
butanol [(rac)-2f], (rac)-4-(4-methoxyphenyl)-2-butanol [(rac)-2g], (rac)-4-(4-
hydoxyphenyl)-2-butanol [(rac)-2h], (rac)-4-phenyl-3-buten-2-ol [(rac)-2i], (rac)-4-
phenyl-3-butyn-2-ol [(rac)-2j], (rac)-1-(2-chlorophenyl)-2-propanol [(rac)-2l], (rac)-
1-(3-(trifluoromethyl)phenyl -2-propanol [(rac)-2m], (rac)-1-phenyl-2-butanol 
[(rac)-2n], (rac)-1-phenyl-2-pentanol [(rac)-2o], and (rac)-1,2-diphenylethanol 
[(rac)-2q], were produced by reducing their corresponding ketones with NaBH4 as 
reported [42].  
8  
9 3.2 Gene expression and purification of TeSADH mutants 
10             W110A, W110G, W110V and W110A/I86A mutants of TeSADH were 
constructed, expressed and purified as previously reported [43]. 
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11 3.3 General procedure for asymmetric reduction of substituted 2-
tetralones and other phenyl ring containing ketones 
3.3.1 Small scale reduction reactions  
12              The asymmetric reduction reactions of substituted 2-tetralones and other 
phenyl ring containing ketones by TeSADH mutants were conducted according to a 
published procedure with some modifications [44,45]. The ketone (0.0191 mmol) 
was added to a solution containing the enzyme (0.2-0.4 mg), NADP+ (1.0 mg) in 
Tris-HCl buffer solution (700 μL, 50 mM, pH 8.0). And 2-propanol (300 μL) in a 
1.5-mL Eppendorf tube. The mixture was shaken in a thermostated shaker at 50 oC 
and 180 rpm for 24 h. W110V TeSADH-catalyzed reactions were carried out by 
using ketones (0.00382 mmol) in Tris-HCl containing  2-propanol (95:5, v/v) 
followed by the addition of ZnCl2 (5 μL of 0.27 mM) and DDT (1.0 mg) were added 
to I86A/W110A TeSADH-catalyzed reduction reactions. The enzyme loading and 2-
propanol concentrations were varied to achieve maximum conversion for selected 
substrates. The reaction mixture was then extracted with ethyl acetate (2 × 500 µL). 
The combined organic layers were dried with sodium sulfate and concentrated. The 
remaining residue was treated with acetic anhydride (5 μL) and pyridine (10 μL) to 
obtain the acetate ester derivative prior to ee determination by chiral GC [46] .The ee 
of substrates (2q, 2v) were analyzed by a chiral HPLC. 
13  
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3.3.2 Large-scale asymmetric reduction reactions  
14               Reaction was carried out on 10-fold scale  by using ketones (0.191 mmol) in 
Tris-HCl buffer solution (50 mM, pH 8.0) containing 2-propanol (10 mL, 70:30, v/v), 
enzyme (0.2-0.4 mg) and NADP+ (2 mg). The reaction was carried out at 50 oC and 
180 rpm in 50 mL round-bottomed flasks. The reaction mixture was then extracted 
with ethyl acetate (2 × 7 mL) and combined organic layers were dried with sodium 
sulfate, concentrated and derivatized as described previously prior to GC analysis. 
Whereas (2q, 2v) were analyzed by HPLC, (R)-1,2-diphenylethanol and 1,3-
diphenyl-2-propan-1-ol were purified by flash chromatography using a mixture of 
ether:hexane (1:3, v/v), and ethyl acetate:hexane (1:1, v/v), respectively. (R)-8-
Methoxy-2-tetralol and (S)-6-chloro-2-tetralol were also purified using by flash 
chromatography using a mixture of ether: hexane (4:1).  
15 3.4 Characterization and Quantification of reduction Products  
16 To confirm the chemical identity of the produced alcohols, the purified alcohols were 
characterized by various spectroscopic techniques including NMR (1H and 13C), IR, 
and mass spectrometry (MS). To identify the stereochemical identity of the produced 
alcohols, their optical rotation were measured by polrimetry, and were then compared 
with the reported values. The % ee of alcohols (1q, 1v) was determined by HPLC 
equipped with a chiral column, whereas for other produced alcohols were 
transformed to their acetate derivatives prior to their analysis by a GC equipped with 
a chiral column.   
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17 3.5 GC analysis (chiral) 
18              The ee of ester derivatives was determined by Agilent GC model 7890A 
equipped with an HP chiral-20B column (30 m, 0.32 mm [i.d.], 0.25 μm film 
thickness) using He as the carrier gas and using flame ionization detector (FID). The 
following temperature program was used for ( 2a-c , 2e, 1j, 1l, 1o): Oven 70 oC 
(initial, hold time 10 min) to 220 oC (final, hold time 10 min) at 1.5 oC/min rate; 
Injector-220 oC, detector 230 oC, He flow rate of 15 mL/min. Injection volume was 
1.0 µL with split ratio 10:1. For 2d and  the temperature program used was: Oven 70 
oC (initial, hold time 10 min) to 220 oC (final, hold time 10 min) at 0.3 oC/min rate; 
Injector-220 oC, detector 230oC, He flow rate of 15 mL/min. Injection volume was 
1.0 µL with split ratio 10:1. On the other hand, the following temperature program 
was used for (1f-1i, 1k, 1m, 1n, 1p, 1s, 1u) for GC oven 70 oC (initial, hold time 10 
min) to 180 oC (final, hold time 20 min) at 5 oC/min rate; injector 220 oC, detector 
230 oC, Helium flow rate is 15 mL/min. Injection volume was 1.0 µL with split ratio 
10:1. 
19 3.6 HPLC analysis (chiral) 
20               The ee of produced alcohol was determined (Agilent HPLC model) using 
hexane/methanol (v/v = 95: 5) as a mobile phase for 1q, while for 1v the mobile 
phase was hexane/2-propanol (v/v = 95: 5). 
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21 3.7 GC-MS analysis (non-chiral): 
22                 GC-MS analysis was conducted using Agilent GC model 7890A and 
Agilent 5975C Inert MSD with Triple-Axis Detector using capillary column [(5% 
phenyl)–methylpolysiloxane, 30 m × 320 µm × 0.25 µm]. The following temperature 
program was used for GC: Oven 70 oC (initial, hold time 10 min) to 180 oC (final, 
hold time 20 min) at 1.5 oC/min rate; Injector 220 oC, detector 230 oC, Helium flow 
rate is 15 mL/min. Injection volume was 1.0 µL with split ratio 10:1.  
23  
24 3.8 Enzyme kinetics  
25              Enzyme kinetic assays were performed according to published procedures 
with some modifications [47, 48]. Reduction reaction rates were measured by 
tracking the consumption of NADPH spectrophotometrically at 340 nm (∆ε= 6220 
M-1.cm-1). The kinetic assays were conducted in cuvettes containing Tris-HCl buffer 
solution (pH 6.5, 50 mM), NADPH (0.25 mM), CH3CN (10%, v/v), and ketone 
substrate (0.05-15 mM) in a total volume of 1.2 mL at 50 °C. The cuvettes were 
incubated for about 15 minutes at 50 °C prior to the addition of enzyme, which was 
also pre-incubated separately at the same temperature. To determine the kinetic 
parameters, activity was determined with at least six substrate concentrations in the 
range of (0.001-15 mM) in triplicate. The Km and Vmax were calculated using Origin . 
26  
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27 3.9 Characterization of Products 
28  
29  (S)-2-Tetralol [(S)-2a] 
30  
31  
32  
33  
Pale yellow oil [ ]!
"#$= − 17.7° (c 0.011, EtOH), 69% ee, [lit. [49] [ ]!
"% = − 20.8° 
(c 0.25, MeOH, 29 % ee (S)]; 1H NMR (500 MHz, CDCl3) : δ 1.69-1.82 (m, 2H), 2.03 (s, 
1H), 2.73-2.96 (m, 3H), 3.08 (dd, J = 3.9, 15.6 Hz, 1H), 4.15-4.23 (m, 1H), 7.09-7.24 (m, 
4H); 13C NMR (125 MHz, CDCl3) : δ 27.0, 31.5, 38.4, 67.2, 125.8, 125.7, 128.6, 129.5, 
134.2, 135.6; RT-IR (neat) 3339 (br), 3060 (m), 3018 (m), 2926 (m), (m) cm-1; EI MS 
m/z (relative intensity) 148 (M+] (12), 131 (12), 130 (100), 129 (42), 128 (12), 115 (27), 
105 (14), 104 (59), 103 (18), 91 (16), 78 (14), 77 (10). 
34  
35  (R)-5-Methoxy-2-tetralol [(R)-2b] 
36  
Pale yellow oil [ ]!
"# = + 12.5° (c 0.008, EtOH), 61 % ee, [lit [50] [ ]!
"$= + 57° (c 0.25, 
EtOH, 88 % ee (R)]; 1H NMR (500 MHz, CDCl3) : δ 1.78-1.87 (m, 2H), 2.04-2.14 (m, 
1H), 2.62-2.74 (m, 1H), 2.93 (dt, J = 4.8, 18.9 Hz, 1H), 3.07 (dd, J = 4.3, 16.2 Hz, 1H), 
3.81 (s, 3H), 4.12-4.18 (m, 1H), 6.66 (d, J = 8.2 Hz, 1H), 6.70 (d, J = 7.4 Hz, 1H), 7.12 
(t, J = 8.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) : δ 21.2, 31.0, 38.4, 55.2, 67.0, 107.2, 
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121.6, 124.5, 126.4, 135.6, 157.1; FT-IR (neat) 3060 (m), 3018 (m), 2926 (m), 2840 (m) 
cm-1; EI MS m/z (relative intensity) 178 [M+] (76), 160 (100), 145 (57), 134 (35), 104 
(53), 91 (42), 51 (6).  
 
37  (S)-7-Methoxy-2-tetralol [(S)-2c] 
38  
Pale yellow oil [ ]!
"# = − 20.4° (c 0.0069, EtOH) (> 99 % ee), (lit. [50] [ ]!
"$%= + 45° 
(c = 0.22, EtOH, 88 % ee (R)); 1H NMR (500 MHz, CDCl3) : δ 1.79-1.90 (m, 2H), 2.01-
2.14 (m, 1H), 2.70-2.75 (m, 2H), 2.85-2.88 (m, 1H), 3.03 (dd, J = 4.0, 16.2 Hz, 1H), 3.75 
(s, 3H), 4.10-4.19 (m, 1H), 6.60 (s, 1H), 6.68 (dd, J = 1.8, 8.6 Hz, 1H), 6.99 (t, J = 8.2 
Hz, 1H); 13C NMR (125 MHz, CDCl3) : δ 26.1, 31.7, 38.65, 55.3,  67.3, 112.0, 114.0, 
127.7, 129.5, 135.4, 157.8; RT-IR (neat) 3060 (m), 3018 (m), 2926 (m), 2840 (m) cm-1; 
EI MS m/z (relative intensity) 178 (76) [M+], 160 (100), 145 (57), 134 (35), 104 (53), 91 
(42), 51 (6). 
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39 (R)-8-Methoxy-2-tetralol [(S)-2d] 
40  
Pale yellow oil [ ] 
!"#= + 52.41° (c 0.00145, EtOH) (> 99 % ee), (lit. [50] [$] 
!% = + 48.6° 
(c = 0.27, EtOH, 98 % ee (R)) ; 1H NMR (500 MHz, CDCl3) : δ (ppm) 1.60-1.63 (m, 1H), 
1.79-1.81 (m, 1H), 1.99-2.02 (m, 1H), 2.55 (dd, J = 7.6, 17.1 Hz, 1H), 2.82-2.85 (m, 1H), 
2.94 (dt, J = 5.8, 17.1 Hz, 1H), 3.08 (dd, J = 5.1, 17.4 Hz, 1H), 3.81 (s, 3H),  3.99-4.17 
(m, 1H), 6.67 (d, J = 8.2 Hz, 1H), 6.72 (d, J = 7.9 Hz, 1H), 7.09 (t, J = 7.6 Hz, 1H); 13C 
NMR (125 MHz, CDCl3) : δ 27.1, 31.1, 32.6, 55.4, 67.4, 107.1, 120.8, 123, 126.3, 137.2, 
157.53; FT-IR (neat) 3060 (m), 3018 (m), 2926 (m), 2840 (m) cm-1; EI MS m/z (relative 
intensity) 178 [M+] (59), 160 (78), 145 (43), 134 (64), 129 (38), 115 (53), 104 (100), 91 
(93), 77 (40), 65 (33), 51 (21). 
41  
42 (S)-6-Chloro-2-tetralol [(S)-2e] 
43  
Pale yellow oil [$] 
!"#= − 43° (c 0.002, CHCl3) (> 99 % ee), (lit. [51] [$] 
'( = − 20.8° (c 
1.1, CHCl3); 
1H NMR (500 MHz, CDCl3) : δ 1.76-1.84 (m, 1H), 1.99-2.05 (m, 1H), 2.71 
(dd, J = 7.6, 16.4 Hz, 1H),  2.76-2.83 (m, 1H), 2.94 (dt, J= 6.1, 17.1 Hz, 1H), 3.03 (dd, J 
= 4.8, 16.6 Hz, 1H), 4.15-4.18 (m, 1H), 6.99-7.09 (m, 3H); 13C NMR (125 MHz, CDCl3) 
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: δ 26.6, 31.0, 37.8, 66.9, 126.0, 128.3, 132.6, 130.3, 137.5, 131.5; FT-IR (neat) 3339 
(br), 3060 (m), 3018 (m), 2926 (m), 2840 cm-1; EI MS m/z (relative intensity) 182 (20) 
[M+], 164 (43), 138 (57), 129 (100), 115 (25), 103 (43). 
 
44                                                
45 (R)-1-(2-Chlorophenyl)propan-2-ol [(R)-2l]: [ ]!
"# = – 20° (c 0.011, CH2Cl2) 80 % 
ee, lit.[52] $[ ]!
"% = + 40.3 (c 1.0, CH2Cl2), 95% ee for S isomer. 
1H NMR (500 MHz, 
CDCl3): δ 1.27 (d, J = 6.1 Hz, 3H), 1.54 (br s, 1H, OH), 2.83 (dd, J = 7.9, 13.7 Hz, 
1H), 2.96 (dd, J = 4.6, 13.6 Hz, 1H), 4.12-4.16 (m, 1H), 7.16-7.38 (m, 4H). 13C NMR 
(125 MHz, CDCl3): δ 23.0, 43.2, 67.5, 126.7, 127.9, 129.6, 131.7, 134.3, 136.4. RT-
IR (neat) 3364 (m), 3057 (m), 2917 (m) cm-1. EI MS m/z (relative intensity) 155 (8), 
126 (85), 91 (100), 66 (15), 45 (50). 
46  
47         (S)-1-(2-chlorophenyl) propan-2-ol [(S)-2l]   
48  
49 (S)-1-(2-Chlorophenyl) propan-2-ol [(S)-2g]: [ ] 
!! = + 11° (c 0.009, CH2Cl2) 
98 % ee, lit. [52] ["] 
!# = + 40.3 (c 1, CH2Cl2), 95% ee for S isomer.  
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50  (R)- 1-phenylpentan-2-ol [(R)-2o]  
51  
 ["] 
!$%= – 1.01 ° (c 0.015, EtOH) (61.5 % ee), [lit. [53] ["] 
!#%= + 3.7° (c 1.1, EtOH, (S)] 
99% ee for S isomer. 1H NMR (500 MHz, CDCl3): δ 0.92-0.95 (t,
 J = 7.0 Hz, 3H), 1.41-
1.53 (m, 4H), 2.65 (dd, J = 8.5, 13.6 Hz, 1H), 2.83 (dd, J = 13.6, 4.0 Hz, 1H), 3.67 (br s, 
OH), 3.81-3.86 (m, 1H), 7.19-7.35 (m, 5H). 13C NMR (125 MHz, CDCl3) : δ 44, 72, 39, 
19, 14, 138, 129, 128, 126. RT-IR (neat) 3347 (m), 3018 (m), 2920 (m) cm-1. EI MS m/z 
(relative intensity) 121 (8), 92 (100), 55 (21), 32 (91). 
 
52  (R)-1, 2-diphenylethanol [(R)-2q] 
53  
 ["] 
!" = + 7.4° (c 0.0157, CHCl3) (> 99 % ee), lit. [54] [#] 
!!$= – 13.0 (c = 1.049, 
CHCl3), 90% ee for S isomer. 
1H NMR (500 MHz, CDCl3): δ 1.93 (br s, 1H), 2.99 (dd, J 
= 8.6, 13.7 Hz, 1H), 3.05 (dd, J = 4.6, 13.6 Hz, 1H), 4.88-4.92 (m, 1H), 7.19–7.37 (m, 
10H). 13C NMR (125 MHz, CDCl3): δ 46.0, 75.0, 125.8, 126.6, 127.6, 128.4, 128.5, 
129.5, 138.0, 144.0; FT-IR (neat) 3404 (br), 3084 (w), 3062 (w), 2924 (m) cm-1. EI MS 
m/z (relative intensity) 198 (2) [M], 107 (72), 92 (100), 77 (56), 51 (12), 39 (8). 
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54  (R)-1, 3-diphenylpropan-1-ol [(R)-2r] 
55  
[#] 
!% = + 5° (c 0.005, CHCl3), lit. [55]  [#] 
!' = – 23.6 (c 0.64, CH2Cl2) 96% ee for S 
isomer. 1H NMR (500 MHz, CDCl3): δ 2.46–2.99 (m, 2H), 3.50–3.58 (m, 3H),), 4.55-
4.59 (m, 1H), 7.22–7.56 (m, 8H) 7.88-7.95 (m, 2H), 7.39-7.42 (d, J= 4.2 Hz, 4H). 13C 
NMR (125 MHz, CDCl3): δ 35.5, 45.4, 72.0, 127.5, 127.8, 127.9, 128.0, 128.6, 128.7, 
133.4, 137.0. FT-IR (neat) 3385 (br), 3053 (w), 3024 (w), 2917 (m) cm-1. EI MS m/z 
(relative intensity) 207 (100), 179 (22), 161 (11), 131 (33), 103 (33), 77 (66), 51 (27). 
 
56 (R)-2-hydroxy-1-phenylpropan-1-one [(R)-2s]  
57  
Pale yellow oil [ ]!
"# = – 4.8° (c 0.0075, CHCl3) (> 99 % ee), [lit. [56] [ ]!
"$ = – 67.0 (c 
0.4, CHCl3), > 99% ee for R isomer. 1H NMR (500 MHz, CDCl3): δ 1.46 (d, J = 7.0 Hz, 
3H), 3.7 (s, 1H), 5.17 (q, J = 7.6 Hz, 1H), 7.37 (d, J = 6.7 Hz, 1H), 7.51 (t, J = 7.6 Hz, 
1H), 7.62 (t, J = 5.0 Hz, 1H), 7.93 (d, J = 7.6 Hz, 2H). 13C NMR (125 MHz, CDCl3): δ 
22.3, 69.3, 128.7, 128.9, 133.4, 134.0, 202.4. FT-IR (neat) 3334 (m), 2954 (w), 2923 cm-
1. EI MS m/z (relative intensity) 105 (100), 77 (50), 51 (14), 43 (11). 
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58  (R)-4, 4, 4-trifluoro-3-hydroxy-1-phenylbutan-1-one [(R)-2v] 
 
 [ ] 
!" = + 0.69° (c 0.0115, MeOH) (> 99 % ee), [lit. [57] [#] 
$%'= + 1.9° (84% ee (R)), c 
= 1.5, MeOH) ] , 84% ee for R isomer. 1H NMR (500 MHz, CDCl3) : δ 3.2 (dd, J = 2.7, 
18.0, Hz, 1H), 3.39 (dd, J = 9.1, 16.9 Hz, 1H), 3.46 (s, 1H, OH), 4.67-4.72 (m, 1H), 7.51 
(t, J = 7.3 Hz, 3H), 7.63 (t, J = 7.3 Hz, 3H), 7.97 (d, J = 7.3 Hz, 3H). 13C NMR (125 
MHz, CDCl3): δ 38.3, 128.2, 128.9, 134.2, 136.0, 197.6. FT-IR (neat) 3381 (br), 2958 
(m), 2924 (m) cm-1. EI MS m/z (relative intensity) 219 (4) [M], 198 (10), 105 (100), 77 
(50), 51 (17). 
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CHAPTER 4 
RESULTS AND DISCUSSION 
4.1 Asymmetric reduction of substituted 2-tetralones  
                   Enantioselective reductions of substituted 2-tetralones were carried out using 
various mutants of TeSADH (W110G, W110A, W110V, and W110A/I86A) to produce 
the corresponding enantiopure alcohols with high conversions and optical purities. The 
reactions were carried out in Tris-HCl buffer solution containing 2-propanol (30%, v/v), 
which serves both as co-solvent and co-substrate to regenerate the co-enzyme making the 
process catalytic. The use of high concentration 2-propanol was crucial to enhance the 
solubility of substituted 2-tetralone substrates and to shift the equilibrium of the reaction 
towards the product. We have reported earlier that the asymmetric reduction of phenyl-
ring-containing ketones using W110A TeSADH produces the corresponding S alcohols, 
whereby the NADPH cofactor transfers its pro-R hydride to the re face of the ketone (i.e., 
Prelog mode).  Thus, the asymmetric reduction of 2-tetralone (1a) using W110A 
TeSADH produced (S)-2-tetralol [(S)-2a] in 71% ee [16]. The low ee could be attributed 
to the small size of 2-tetralone that allows this substrate to fit in more than one orientation 
allowing selectivity mistakes to occur. This moderate enantioselectivity of 1a encouraged 
us to explore the asymmetric reduction of 1a and its substituted analogs (1b-d), using 
various mutants of TeSADH. It was intended to study the effect of the substituent of the 
phenyl ring of 2-tetralone on the enantioselectivity of the reduction reaction. 
 Therefore, we tried the asymmetric reduction of 1a by various mutants of 
TeSADH and the enantioselectivity and the conversion of these reactions are reported in 
(Table 6). A moderate enantioselectivity and high percent conversion were obtained with 
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W110G TeSADH; these results are similar to those obtained previously with W110A 
TeSADH [16]. A noticeable increase in enantioselectivity was observed with W110V 
TeSADH, but with low percent conversion; this higher enantioselectivity may be due to 
the smaller size of the large pocket of W110V TeSADH compared to W110G and 
W110A TeSADHs, that signifies the impact on enantioselectivity by a small alteration in 
the active site of TeSADH. A similar trend in the enantiospecific oxidation of 1-phenyl-
2-propanol by W110V TeSADH compared to W110G and W110A TeSADHs was 
observed previously [46]. The use of W110A/I86A TeSADH, which was designed to 
enlarge both pockets of TeSADH, in asymmetric reduction of 1a resulted in moderate 
enantioselectivity and low conversion. The resultant alcohol has S configuration with the 
four mutant enzymes.    
 
Table 6: Small-scale asymmetric reduction of substituted 2-tetralones by different 
mutants of TeSADH.[a]  
 
Substrate Product Enzyme 
(mutant 
TeSADH) 
Conv. 
(%)[b] 
ee 
(%)[c] 
 
 
 
 
 
 
W110G > 99 69 
W110A[d] > 99 71 
W110V 5 91 
W110A/I86A 12 74 
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W110G > 99 61 
W110A 99 87 
W110V 96 71 
W110A/I86A > 99 95 
 
 
 
 
W110G > 99 > 99 
W110A 99 > 99 
W110V 46 > 99 
W110A/I86A > 99 > 99 
 
 
 
 
 
W110G > 99 > 99 
W110A 99 > 99 
W110V 67 > 99 
W110A/I86A 94 > 99 
 
 
 
 
 
W110G > 99 > 99 
W110A 99 > 99 
W110V 86 > 99 
W110A/I86A 95 > 99 
[a] Unless otherwise stated, reactions were performed using ketone [1a–e (0.0191 mmol)], TeSADH 
mutant (0.2 mg), NADP+ (1.0 mg), Tris-HCl buffer solution (700 μL, 50 mM, pH 8.0), and 2-propanol (300 
μL); for W110A/I86A TeSADH-catalyzed reduction reaction, ZnCl( (5 μL of 0.27 mM) and DTT (1.0 mg) 
were also added; for W110V TeSADH-catalyzed reduction reactions, [1a–e (0.0038 mmol)], Tris-HCl 
buffer solution (950 μL, 50 mM, pH 8.0), and 2-propanol (50 μL) were used. [b] Percent conversion was 
determined by GC. [c] The % ee of the corresponding acetate ester derivative of the alcohol product was 
determined by GC using a chiral stationary phase. [d] [16]. 
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The enantioselective reduction of 5-methoxy-2-tetralone (1b) using W110G, W110A, 
W110V, and W110A/I86A TeSADHs resulted in the formation of (R)-5-methoxy-2-
tetralol [(R)-2b] with high percent conversion and moderate to high ee, as shown in 
(Table 6). Whereas W110G TeSADH and W110A/I86A TeSADH turned out to be least 
and most selective mutants respectively, the W110V TeSADH and W110A TeSADH 
were ranged moderate in selectivity. These results demonstrate that even a small 
alteration in the active site of the enzyme significantly affects its enantioselectivity. In all 
cases, the resultant alcohol has the R configuration, which revealed that the presence of 
the methoxy group dictates the fit of 1b in the active site. In contrast to 1a, the fit of 1b 
was in opposite fashion i.e., the hydride delivery to the si face of the substrate rather than 
to the re face.  
 The asymmetric reduction of 7-methoxy-2-tetralone (1c) using W110G, 
W110A, and W110A / I86A TeSADHs resulted in the formation of 7-methoxy-2-tetralol 
[(S)-2c] with high enantioselectivity and percent conversion. Reaction with W110V 
TeSADH produced the same (S)-2c in high enantioselectivity, but a moderate percent 
conversion, possibly due to the smaller large pocket of this mutant compared to the other 
mutants. In all cases, the resultant alcohol has the S configuration, which is in agreement 
with Prelog rule. The asymmetric reduction of 8-methoxy-2-tetralone (1d) produced (R)-
8-methoxy-2-tetralol [(R)-2d] with a similar fashion as was the with 1c, but with opposite 
stereopreference. The asymmetric reduction of 6-chloro-2-tetralone (1e) with W110G, 
W110A, W110V and W110A/I86A mutants of TeSADH produced the corresponding S 
alcohols in high enantioselectivities and high percent conversions. The inverted 
stereoselectivity noticed in the enantioselective reductions of 1b and 1d showed the great 
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influence of the position of the substituent on the aromatic ring that dictates the binding 
mode of the substrate in the active site, and hence the stereochemical outcome.  
 The same reduction was carried out in a larger scale using W110G TeSADH, 
since this mutant gave the highest percent conversion of the four mutant enzymes (Table 
7). Slightly lower percent conversions were obtained in the large-scale reduction 
reactions of 1d (95 %) and 1e (93 %) compered to their small scale reactions, possibly 
due to product inhibition. However, for the other substrates the percent conversion and % 
ee were almost identical compared to small scale reactions. 
Table 7: Large-scale asymmetric reduction of substituted 2-tetralones by W110G 
TeSADH.[a] 
 
Substrate Product Conv. 
(%)[b]   
ee 
(%)[c] 
1a (S)-2a > 99 69 
1b (R)-2b > 99 61 
1c (S)-2c > 99 > 99 
1d (R)-2d 95 > 99 
1e (S)-2e 93 > 99 
[a] Unless otherwise stated, reactions were performed by using ketone [(1a–e (0.191 mmol)], W110G 
TeSADH (0.2 mg), NADP+ (1.5 mg), and 2-propanol (30%, v/v). [b] % Conversion was determined by GC. 
[c] The % ee of the corresponding acetate ester derivative of the alcohol product was determined by GC 
using a chiral stationary phase. 
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 To study the effect of the substituent on the aromatic ring of the 2-tetralone on 
the binding affinity and maximum rate, we measured Michaelis-Menten constant (Km) 
and maximum rate (Vmax) of W110A and W110G TeSADH for substrates 1a-c (Table 8). 
The lowest Km values of W110G and W110A TeSADHs were obtained for 1a. Thus, one 
would expect that 1a may be reduced with high enantioselectivity by these two mutant 
enzymes, which was not the case in reality (Table 6).  The fact that due to the light there 
is little difference in the size of the two alkyl sides of the carbonyl of 1a would allow for 
more than one binding mode that increased the chances for selectivity mistakes. It is 
predominant to note that the Km of W110A TeSADH for three substrates is almost three 
times lower than that of W110G TeSADH. The smaller size of the large pocket of 
W110A TeSADH than that of W110G TeSADH could better guide the proper fit of these 
substrates within the active site of W110A TeSADH. These findings indicated the 
importance of residue 110 in substrate binding through Van der Waals interactions, as 
suggested in the crystal structure of TbADH-2-butanol binary complex [12,58] The low 
Km values of W110A TeSADH for 1a-c were supported by the higher observed ee values 
in the asymmetric reduction reactions of 1a and 1b, using the same mutant as compared 
with those obtained with W110G TeSADH (Table 1). Addition of a methoxy group to the 
aromatic ring resulted in higher Km values than for 1a (1.3-fold increase for 1b vs. 2.5-
fold increase for 1c). The Vmax values for 1a-c with both mutants were comparable to 
each other, which indicated that the methoxy substituent does not have a pronounce effect 
on Vmax. 
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Table 8: Kinetic parameters of W110G and W110A TeSADH for asymmetric reduction 
of 1a-c.[a] 
 
Ketone W110G TeSADH W110A TeSADH 
Km (mM) Vmax (mM.min-1) Km (mM) Vmax (mM.min-1) 
1a 0.0184 ± 0.000824 0.0748 ± 0.00335 0.00580 ± 0.00029 0.0589 ± 0.0048 
1b 0.0231 ± 0.0011 0.0666 ± 0.00316 0.0106 ± 0.000528 0.0695 ± 0.0039 
1c 0.0452 ± 0.00156 0.0743 ± 0.00257 0.0122 ± 0.000611 0.0545 ± 0.00218 
[a] Unless otherwise stated, reactions were performed at 50 °C by using ketone [1a–c (0.001-15 mM)], 
TeSADH mutant (0.002 mg), NADPH (0.25 mM), and acetonitrile (10%, v/v). 
 
4.2 Asymmetric reduction of other phenyl-ring-containing ketones 
 
To check the efficiency of W110A/I86A TeSADH in asymmetric reduction of 
phenyl-ring-containing ketones that served as substrates for W110A TeSADH [47], we 
conducted an extensive study on the activity and stereoselectivity of various W110 
mutants (W110A, W110G and W110V) in asymmetric reduction of these ketones and 
compared them to those obtained by W110A/I86A TeSADH. Most of the reactions were 
performed in Tris-HCl buffer solutions containing 2-propanol (30%, v/v), which works as 
a co-solvent and co-substrate. The four mutants tested have showen similar activities and 
enantioselectivities in the asymmetric reduction of 4-phenyl-2-butanone (1f) and 
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produced the corresponding (S)-4-phenyl-2-butanol [(S)-2f] in high coversions and 
enantioselectivities (Table 9). The single mutants (W110A, W110G and W110V) 
performed slightly better than the double mutant (W110A/I86A) in the asymmetric 
reductions of 4-(4'-methoxyphenyl)-2-butanone (1g) and 4-(4'-hydoxyphenyl)-2-butanone 
(1h). However, W110A/I86A TeSADH showed the best performance and higher 
stereoselectivity than the single mutants in the asymmetric reduction of 1g (Table 9). The 
W110G TeSADH mutant showed the least stereoselectivity in the reduction of 1g, which 
is consistent with previously reported results [47]. It is well noted that the activity and 
stereoselectivity of TeSADH-catalyzed reduction reactions are highly dependent on the 
structures of both the mutant and the substrate. The high ee (> 94%) registered in the 
asymmetric reduction of 1h using all mutants when compared with 1g could be due to 
better binding affinity of hydroxyl group with the active site of the enzyme  compared to 
methoxy group, that led to less selectivity mistakes. Low conversion was observed in the 
W110A/I86A TeSADH-catalyzed reduction of 4-phenyl-3-buten-2-one (1i) compared to 
those obtained with single mutants (Table 9). However, the asymmetric reduction of 4-
phenyl-3-butyn-2-one (1j) resulted in high conversion and high ee with all mutants 
(Table 9). The asymmetric reduction of 1j in a high enantioselectivity is of great interest 
since this substrate, known as a difficult substrate, which is difficult to be reduced with 
high enantioselectivity [59]. During optimization of the co-substrate concentration we 
observed an increase in the stereoselectivity in the asymmetric reduction of 1g and 1h by 
employing 10% (v/v) of 2-propanol, as compared to 30% (v/v) for 1f, 1i and 1j. This 
outcome could be attributed to the intermolecular hydrogen bonding between the 
substrate and co-substrate. All of these substrates (1f-j) were reduced in Prelog mode by 
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the four mutants tested, leading to the produced alcohols in S configuration. The ability of 
W110A/I86A TeSADH to reduce these substrates with similar efficiencies to those 
obtained by the single mutants is charming. It is worth mentioning that W110A/I86A 
TeSADH was first designed to expand the two pockets of the active site as part of our 
effort to increase selectivity mistakes and thus increase its efficiency in racemization of 
enantiopure alcohols [43].   
 
Table 9:  Asymmetric reduction of phenyl-ring-containing ketones by different mutants 
of TeSADH.a 
 
 R Substrate X Conv. 
(%)b 
ee 
(%)c 
 PhCH2CH2 1f W110G
e > 99 96 
   W110Ae 99 99 
   W110Ve 95 > 99 
   W110A/ I86A 91 98 
 p-MeO-C6H4-CH2CH2 1g
d W110G 93 20 
   W110Af 98 60 
   W110V 94 79 
   W110A I86A 40 84 
 p-HO-C6H4-CH2CH2 1h
d W110G 95 99 
   W110A 97 > 99 
   W110V 92 94 
   W110A I86A 80 > 99 
 (E)-Ph-HC=CH 1i W110G 75 > 99 
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   W110Af 73 92 
   W110V 67 92 
   I86A/W110A 21 90 
 Ph-C≡C 1j W110G > 99 97 
   W110A 99 99 
   W110V 97 > 99 
   I86A/W110A > 99 98 
aUnless otherwise stated, reactions were performed using ketone 1f–j (0.0191 mmol), TeSADH mutant [0.2 
mg in 100 μL of Tis-HCl buffer solution (20 mM, pH 8.0)], NADP+ (1.0 mg), Tris-HCl buffer solution 
(700 μL, 50 mM, pH 8.0), and 2-propanol (300 μL); for W110A/I86A TeSADH-catalyzed reduction 
reactions, ZnCl  (5 μL of 0.27 mM) and DTT (1.0 mg) were also added; for W110V TeSADH-catalyzed 
reduction reactions, 1f–j (0.0038 mmol), Tris-HCl buffer solution (950 μL, 50 mM, pH 8.0), and 2-
propanol (50 μL) were used. bPercent conversion was determined by GC. cThe % ee of the corresponding 
acetate ester derivative of the alcohol produced was determined by GC using a chiral stationary phase. 
dReactions were performed using 10% of 2-propanol. eResults from Patel et al. Org. Biomol. Chem. 2014, 
12 (31), 5905–5910. fResults from Musa et al. J. Org. Chem. 2007, 72 (2), 30–34. 
 
 
Table 10: Asymmetric reduction of phenyl ring-containing ketones by various mutants of 
TeSADH.a 
 
 R1 R2 Substrate X Conv. 
(%)b 
ee 
(%)c 
 PhCH2 CH3 1k W110G
d > 99 79(S) 
    W110Ad 95 84(S) 
    W110Vd > 99 > 
99(S) 
    W110A/I86A > 99 80(R) 
 o-Cl-C6H4-CH2 CH3 1l W110G 13 89(S) 
    W110A 84 98(S) 
    W110V 99 > 
99(S) 
    W110A/I86A > 99 99(R) 
 m-CF3-C6H4-CH2 CH3 1m W110G > 99 96(S) 
    W110A > 99 > 
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99(S) 
    W110V 99 99(S) 
    W110A/I86A > 99 95(S) 
 PhCH2 CH3CH2 1n W110G
d 96 92(S) 
    W110A 98 92(S) 
    W110Vd 99 > 
99(S) 
    W110A/I86A 72 71(S) 
 PhCH2 CH3CH2CH2 1o W110G n.r. - 
    W110A 3 n.d. 
    W110V 32 92(R) 
    W110A/ I86A 95 98(R) 
 Ph CH3 1p W110G n.r. - 
    W110A n.r. - 
    W110V n.r. - 
    W110A/ I86A 46 98(R) 
aUnless otherwise stated, reactions were performed using ketones 1k–p (0.0191 mmol), TeSADH mutant 
(0.2 mg), NADP+ (1.0 mg), Tris-HCl buffer solution (700 μL, 50 mM, pH 8.0), and 2-propanol (300 μL); 
for W110A/I86A TeSADH-catalyzed reduction reaction, ZnCl2 (5 μL of 0.27 mM) and DTT (1.0 mg) were 
also added; for W110V TeSADH-catalyzed reduction reactions, 1k–p (0.0038 mmol), Tris-HCl buffer 
solution (950 μL, 50 mM, pH 8.0) and 2-propanol (50 μL) were used. bPercent conversion was determined 
by GC. cThe % ee of the corresponding acetate ester derivative of the alcohol produced was determined by 
GC using a chiral stationary phase. [n.r.: no reaction, n.d.: not determined]. dThese results were obtained 
from Patel, J. M. et al. Org. Biomol. Chem. 2014, 12 (31), 5905–5910 (reactions conducted in 5% of 2-
propanol). 
 
 
In an earlier report [47], the asymmetric reduction of 1-phenyl-2-propanone (1k)  
using W110G and W110A mutants of TeSADH produced the corresponding S-
configured alcohol in excellent conversion and moderate ee, whereas the used of W110V 
resulted in significant enhancement in ee (> 99%) . Such an outcome was explained by 
the ability of this substrate to fit in dual modes within the large pocket of the active site of 
W110A and W110G mutants of TeSADH, whereas such dual fit is not allowed in 
W110V because of the smaller size of the large pocket. In the current report, 
W110A/I86A TeSADH-catalyzed reduction of 1k resulted in a reverse stereochemical 
outcome, producing the corresponding R-configured alcohol in high conversion and good 
enantioselectivity (Table 10). The double mutant expands both pockets of TeSADH and 
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thus allowed the benzyl group to fit within the small pocket. This observation which 
indicated that the small pocket of TeSADH has higher affinity for hydrophobic moieties 
compered to its large pocket. The high binding affinity of the small pocket in the 
asymmetric reduction of aliphatic ketones using wild-type TbADH as well documented 
in the literature [7]. Asymmetric reduction of 1-(2'-chlorophenyl) propan-2-one (1l) by a 
s produced (S)-2l in high enantioselectivity, while using the double mutant resulted in the 
opposite enantiomer (R)-2l in high ee (99%). The presence of trifluoromethyl group 
(CF3) in the meta position of 3-(trifluoromethyl)phenylacetone (1m) resulted in reduction 
to (S)-2m in high conversion and high enantioselectivity by all mutants. These 
observations indicated that the CF3 on meta position does not allow substrate to fit within 
the small pocket of W110A/I86A TeSADH as was the case with 1k and 1l do. Likewise 
reduction of 1-phenyl-2-butanone (1n) predominantly produced the S-alcohol in high ees 
when single mutants were used, whereas a moderate ee was observed by using the double 
mutant. The moderate enantioselectivity in the W110A/I86A TeSADH-catalyzed 
asymmetric reduction is due to the ability of the benzyl group to fit in the small pocket, 
giving a substantial amount of R-alcohol.  Extending the alkyl moiety to propyl as in 1-
phenyl-2-pentanone (1o) resulted in a reversed fit of this substrate in the active cite of 
W110A/I86A TeSADH producing (R)-2o in high ee. These findings revealed that 
indicated the propyl group enforces this substrate to fit in an orientation which facilitate 
the hydride delivery from the Si face of the ketone in anti-Prelog mode (i.e., benzyl 
moiety in the small pocket). This trend of reversed stereochemistry was also observed in 
the reduction of 1o, using W110V TeSADH but with low conversion. Surprisingly, 1o 
was not a substrate for W110G and W110A mutants of TeSADH.  
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W110A/I86A TeSADH-catalyzed reduction of acetophenone (1p), which is not a 
substrate for W110G, W110A, and W110V mutants of TeSADH, resulted in (R)-1-
phenylethanol [(R)-2p] in high enantioselectivity and moderate conversion in (Table 10). 
The ketone 1p is a substrate for I86A TeSADH as previously reported [45]. The 
stereochemical outcome with the double mutant in the asymmetric reduction of 1p is 
consistent with the earlier report, wherein 1p was reduced in anti-Prelog mode by using 
I86A TeSADH [45]. Compounds 1f-n are substrates for W110 TeSADH mutants, but are 
not substrates for I86A TeSADH. Similarly 1p is a substrate for I86A but not for W110 
TeSADH mutants. Consequently, simultaneous mutations of W110A and I86A would 
generate a mutant that can reduce ketones, which are substrates for both individual 
mutants (i.e., W110A and I86A mutants of TeSADH). This striking finding prompted us 
to look for more interesting substrates like bulky-bulky ketones in order to expand 
substrate specificity of TeSADH. 
 
 Expanding the sizes of the two pockets of TeSADH in W110A/I86A TeSADH 
makes this mutant a potential catalyst to reduce bulky-bulky ketones such as 1,2-
diphenylethanone (1q), 1,3-diphenyl-2-propen-1-one (1r), which are not substrates for 
W110A or I86A mutants of TeSADH. Reduction of 1q using W110A/I86A TeSADH 
resulted in (R)-2q in high enantioselectivity and high conversion. The ability of this 
mutant to accommodate 1q is attributed to the extension of both the small and large 
pockets of I86A/W110A TeSADH. Reduction of 1q by W110A/I86A mutant followed 
Prelog rule with an inverted Cahn-Ingold-Prelog priority, which indicated that the benzyl 
and phenyl groups were accommodated by the large and small pockets, respectively. 
Reduction of such bulky-bulky substrate with high enantioselectivity is of great interest 
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due to the similar sizes of phenyl and benzyl moieties. Reduction of 1r using 
W110A/I86A TeSADH produced (R)-1,3-diphenylpropan-1-ol [(R)-2r], which is result 
resulted from a Michael addition followed by reduction of the carbonyl function. 
W110A/I86A TeSADH-catalyzed reduction of 1r followed Prelog rule, which indicated 
that due to the phenyl group fits within the small pocket of W110A/I86A TeSADH and 
thus resulted in a Re facial attack. The resultant enantiomers were found to be inseparable 
by both chiral GC or HPLC to determine the percent ee of the product alcohol. Activities 
of W110A/I86A TeSADH-catalyzed reduction of the bulky-bulky substrate such as 1q 
and 1r were clearly better than that of 1p, which is a typical example of a small–bulky 
ketone. These observations are considered due to the proper fit of bulky-bulky substrates 
within the active site of W110A/I86A mutant that allowed for the maximum utilization of 
the active site. 
Table 11: Asymmetric reduction of bulky-bulky ketones by W110A/I86A TeSADH.a 
 
 
 
Substrate Product Conv. (%)b ee (%)c 
1q (R)-2q 87 95 
1r (R)-2r 91 n.d. 
 
aUnless otherwise stated, reactions were performed using ketone [1q or 1r (0.0191 mmol)], W110A/I86A 
TeSADH (0.4 mg), NADP+ (1.0 mg), Tris-HCl buffer solution (700 μL, 50 mM, pH 8.0), and 2-propanol 
(300 μL), ZnCl  (5 μL of 0.27 mM) and DTT (1.0 mg). bPercent conversion was determined by GC. cThe 
% ee for (R)-2q was determined by HPLC hexane/methanol (v/v = 95: 5). n.d.: not determined. 
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An interesting characteristic of enzymes, besides their high enantioselectivity, is 
their high regioselectivity,  a treat difficult to realize by This very important feature that 
is not easy to accomplish using organometallic or organic catalysts. Even though was 
observed in the asymmetric reduction of 1-phenyl-1,3-propanedione (1s), 1-phenyl-1,3-
butanedione (1u), 4,4,4-trifluoro-1-phenyl-1,3-butanedione (1v). Reduction of 1s was not 
possible by using W110 single mutants of TeSADH. However, W110A/I86A TeSADH-
catalyzed reduction of 1s resulted in a regioselective reduction of the homobenzylic 
carbonyl to produce (R)-2-hydroxy-1-phenyl-1-propanone [(R)-2s] in excellent 
conversion (> 99%) and enantioselectivity (> 99%) (Table 12). The production of R-
configured alcohol in asymmetric reduction of 1s indicated that this substrate fits in an 
orientation that allowed si-facial attack of the carbonyl moiety (i.e., anti-Prelog mode). 
This stereochemical outcome was similar to that obtained by W110A/I86A TeSADH-
catalyzed reduction of 1k and 1l (Table 10), which reflected the similarity among the 
three structures. Excellent performance was observed by all the mutants in the 
asymmetric reduction of 1u in Prelog mode predominantly, yielding the (S)-3-hydroxy-1-
phenyl-1-butanone [(S)-2u] leaving the benzylic carbonyl intact. Poor performances were 
observed in the asymmetric reduction of 1v using W110A, W110G and W110A/I86A 
mutants of TeSADH. Surprisingly, W110V TeSADH-catalyzed reduction of 1v that 
resulted in (R)-4,4,4-trifluoro-3-hydroxy-1-phenyl-1-butanone [(R)-2v] in excellent 
conversion (> 99%), enantioselectivity [> 99%] and regionselectivity leaving the benzylic 
carbonyl intact. The (R)-configured alcohol produced in the asymmetric reduction of 1v 
is a result of an inverse Cahn-Ingold-Prelog priority (i.e., the reaction follows Prelog 
rule).   
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Table 12: Regio- and enantioselective reduction of phenyl-ring-containing diketones by 
different mutants of TeSADH.a 
 
 
 R1 R2 Substrate X Product  Conv. 
(%)b 
ee(%)c 
 PhCO CH3 1s W110G (R)-2s n.r. - 
    W110A  n.r. - 
    W110V  n.r. - 
    W110A/I86A  > 99 > 99 
 PhCOCH2 CH3 1u W110G (S)-2u 92 > 99 
      W110Ae  99 > 99 
    W110V  89 > 99 
    W110A/I86A  92 92 
 PhCOCH2 CF3 1v W110G (R)-2v 3 n.d. 
    W110A  8 n.d. 
    W110V  > 99 > 99d 
    W110A/I86A  2 n.d. 
aUnless otherwise stated, reactions were performed using ketone [1s–v (0.0191 mmol)], TeSADH mutant 
(0.2 mg), NADP+ (1.0 mg), Tris-HCl buffer solution (700 μL, 50 mM, pH 8.0), and 2-propanol (300 μL); 
for W110A/I86A TeSADH-catalyzed reduction reactions, ZnCl2 (5 μL of 0.27 mM) and DTT (1.0 mg) 
were also added; for W110V TeSADH-catalyzed reduction reactions, [1s–v (0.0038 mmol)], Tris-HCl 
buffer solution (950 μL, 50 mM, pH 8.0), and 2-propanol (50 μL) were used. bPercent conversion was 
determined by GC. cThe % ee of the corresponding acetate ester derivative of the  alcohol produced was 
determined by GC using a chiral stationary phase. dThe % ee of (R)-2v was determined by HPLC using 
hexane/2-propanol (95:5, v/v). eResults obtained from Musa, M. M. et al. J. Org. Chem. 2007, 72 (2), 30–
34. 
 
The effect of a substituent on the phenyl ring of ketones was investigated by 
measuring the Michaelis-Menten constant (Km) and maximum rate (Vmax) for W110G 
TeSADH-catalyzed reduction reactions of 1g, 1h, and 1m (Table 13). The highest Km 
value was for 1g was observed suggesting a low binding affinity of this substrate within 
the active site of W110G TeSADH, which is consistent with the observed low 
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enantioselectivities observed in the asymmetric reduction of this substrate compared to its 
obtained for 1h and 1m (Table 10). The low Km value obtained for 1h could be attributed 
to the high binding affinity of the hydroxyl group with the active site of W110G 
TeSADH. The least Km was obtained with 1m which is also consistent with the observed 
high enantioselectivity (96%) in the W110G TeSADH-catalyzed reduction of this 
substrate. High binding affinity of the substrate at the active site leads to a more rigid 
substrate orientation reducing selectivity mistakes, and hence improved 
enantioselectivity. 
 
Table 13: Kinetic parameters for the asymmetric reduction of ketones using W110G 
TeSADH.a 
 
 
Substrate Km (mM) Vmax (mM.min
-1) 
1g 2.58418 ± 0.00992 0.08775 ± 0.00225 
1h 0.6993 ± 0.0462 0.04779 ± 0.00316 
1m 0.33455 ± 0.0160 0.0743 ± 0.00356 
aReactions were performed at 50 °C by using ketone [1g, 1h or 1m  (0.005-15 mM)], W110G TeSADH 
mutant (0.002 mg), NADPH (0.25 mM), and acetonitrile (10%, v/v) in Tris-HCl buffer solution (50 mM, 
pH 6.5). R as defined in Table 9 and  table 10. 
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Chapter 5 
CONCLUSION 
In conclusion, we have demonstrated that the double mutation of TeSADH at W110 and 
I86 sites expand substrate scope for W110A/I86A TeSADH. Subsequently, it reduces 
ketones that are substrates for W110 mutants of TeSADH and I86A TeSADH with 
comparable activities and enantioselectivities compered to reduction by the single 
mutants. The expanded pockets of this double mutant also accommodates ketones bearing 
bulky groups on both sides of the carbonyl like 1q and 1r with high activities and 
enantioselectivities. The asymmetric reduction of phenyl-ring-containing ketones was 
undertaking by using W110G, W110A, and W110V mutants of TeSADH and compared 
it with those obtained by W110A/I86A TeSADH. A reverse stereochemical outcome was 
observed the position of the subsistent on the phenyl ring of the 2-teralone was changed. 
Kinetic results indicated that the Km does not only depend on the enzyme mutation, but 
also on the position of the substituent on the aromatic ring of the 2-tetralone. In addition, 
a reverse enantiopreference for few substrates was realized when W110A/I86A TeSADH 
was used. We were also succeeded in conducting regionselective reductions of diketones 
using both the double or single mutants of TeSADH, a feature that is tough to accomplish 
by non-enzymatic approaches. The ability of W110A/I86A TeSADH to accommodate a 
wider scope of substrates than those accommodated by wild-type TeSADH and other 
previously reported single mutants will be of great interest to organic chemists.   
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Appendix  
1. GC Chromatograms 
 
a) 
 
b) 
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c) 
 
 
d) 
 
Figure A15. GC Chromatogram of: a) acetate derivative of rac-2a (made by reduction of 
1a with NaBH4), b) acetate derivative of (S)-2a prepared by W110G TeSADH, c) acetate 
derivative of (S)-2a prepared by W110A TeSADH, d) acetate derivative of (S)-2a 
prepared by W110A/I86A TeSADH. 
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a) 
 
 
b) 
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c) 
 
 
d) 
 
Figure A16. GC Chromatogram of: a) acetate derivative of rac-2b (made by reduction of 
1b with NaBH4), b) acetate derivative of (S)-2b prepared by W110G TeSADH, c) acetate 
derivative of (S)-2b prepared by W110A TeSADH, d) acetate derivative of (S)-2b 
prepared by W110A/I86A TeSADH. 
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a) 
 
b) 
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c) 
 
d) 
 
Figure A17. GC Chromatogram of: a) acetate derivative of rac-2c (made by reduction of 
1c with NaBH4), b) acetate derivative of (S)-2c prepared by W110G TeSADH, c) acetate 
derivative of (S)-2c prepared by W110A TeSADH, d) acetate derivative of (S)-2c 
prepared by W110A/I86A TeSADH. 
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a) 
 
b) 
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c) 
 
 
d) 
 
Figure A18. GC Chromatogram of: a) acetate derivative of rac-2d (made by reduction of 
1d with NaBH4), b) acetate derivative of (S)-2d prepared by W110G TeSADH, c) acetate 
derivative of (S)-2d prepared by W110A TeSADH, d) acetate derivative of (S)-2d 
prepared by W110A/I86A TeSADH. 
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a) 
 
* Alcohol product due to incomplete derivatization. 
 
b) 
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c) 
 
d) 
 
 
Figure A19. GC Chromatogram of: a) acetate derivative of rac-2e (made by reduction of 
1e with NaBH4), b) acetate derivative of (S)-2e prepared by W110G TeSADH, c) acetate 
derivative of (S)-2e prepared by W110A TeSADH, d) acetate derivative of (S)-2e 
prepared by W110A/I86A TeSADH. 
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a) 
 
 
b) 
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c) 
 
 
d) 
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e)  
 
Figure A6. GC Chromatogram of: a) acetate derivative of rac-2g (made by reduction of 
1g with NaBH4), b) acetate derivative of (S)-2g with W110G TeSADH, c) acetate 
derivative of (S)-2g with W110A TeSADH, d) acetate derivative of (S)-2g with W110V 
TeSADH,  e) acetate derivative of (S)-2g with W110A/I86A TeSADH. 
 
a) 
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b) 
 
 
c) 
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d)  
 
 
e)  
Figure A7. GC Chromatogram of: a) acetate derivative of rac-2h (made by reduction of 
1h with NaBH4), b) acetate derivative of (S)-2h W110G TeSADH, c) acetate derivative 
of (S)-2h W110A TeSADH, d) acetate derivative of (S)-2h with W110V TeSADH, e) 
acetate derivative of (S)-2h W110A/I86A TeSADH. 
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a) 
 
 
b) 
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c) 
 
d) 
 
77 
 
 
e) 
Figure A8. GC Chromatogram of: a) acetate derivative of rac-2i (made by reduction of 
1i with NaBH4), b) acetate derivative of (S)-2i W110G TeSADH, c) acetate derivative of 
(S)-2i W110A TeSADH, d) acetate derivative of (S)-2i with W110V TeSADH, e) acetate 
derivative of (S)-2i W110A/I86A TeSADH. 
 
a) 
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b) 
 
c) 
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d) 
 
e) 
 
 
Figure A9. GC Chromatogram of: a) acetate derivative of rac-2j (made by reduction of 
1jwith NaBH4), b) acetate derivative of (S)-2j W110G TeSADH, c) acetate derivative of 
(S)-2j W110A TeSADH, d) acetate derivative of (S)-2j W110V TeSADH, d) acetate 
derivative of (S)-2j W110A/I86A TeSADH. 
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a) 
 
 
b) 
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c) 
 
 
d) 
 
 
82 
 
 
e)  
Figure A10. GC Chromatogram of: a) acetate derivative of rac-2l  (made by reduction of 
1l with NaBH4), b) acetate derivative of (S)-2l W110G TeSADH, c) acetate derivative of 
(S)-2l W110A TeSADH, d) acetate derivative of (S)-2l W110VTeSADH, e) acetate 
derivative of (R)-2l W110A/I86A TeSADH. 
 
a) 
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b) 
 
c) 
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d) 
 
e) 
 
Figure A11. GC Chromatogram of: a) acetate derivative of rac-2m (made by reduction 
of 1m with NaBH4), b) acetate derivative of (S)-2m W110G TeSADH, c) acetate 
derivative of (S)-2m W110A TeSADH, d) acetate derivative of (S)-2m W110V 
TeSADH, e) acetate derivative of (R)-2m W110A/I86A TeSADH. 
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a) 
 
b) 
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c) 
 
d) 
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e) 
 
Figure A12. GC Chromatogram of: a) acetate derivative of rac-2n (made by reduction of 
1n with NaBH4), b) acetate derivative of (S)-2n  W110G TeSADH, c) acetate derivative 
of (S)-2n W110A TeSADH, d) acetate derivative of (S)-2nwith W110V TeSADH,  e) 
acetate derivative of (S)-2n W110A/I86A TeSADH. 
 
a) 
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b) 
 
c) 
 
Figure A13. GC Chromatogram of: a) acetate derivative of rac-2o (made by reduction of 
1o with NaBH4), b) acetate derivative of (R)-2o with W110V TeSADH, c) acetate 
derivative of (R)-2o with W110A/I86A TeSADH. 
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a) 
 
b) 
 
Figure A14. GC Chromatogram of: a) acetate derivative of rac-2k (made by reduction of 
1p with NaBH4), b) acetate derivative of (R)-2p with W110A/I86A TeSADH. 
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a) 
 
b) 
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c) 
 
d) 
 
Figure A15. GC Chromatogram of: a) acetate derivative of (S)-2u W110G TeSADH, b) 
acetate derivative of (S)-2u W110A TeSADH, c) acetate derivative of (S)-2u with 
W110V TeSADH,  d) acetate derivative of (S)-2u W110A/I86A TeSADH. 
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a) 
 
 
b) 
 
Figure A16. HPLC Chromatogram of: a) rac-2q (made by reduction of 1qwith NaBH4), 
b) (R)-2q with W110A/I86A TeSADH. 
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2. Mass spectra 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A17. GC chromatogram and MS spectrum of the (S)-2a prepared by W110G 
TeSADH. 
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Figure A18. GC chromatogram and MS spectrum of the (R)-2b prepared by W110G 
TeSADH. 
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Figure A19. GC chromatogram and MS spectrum of the (S)-2c prepared by W110G 
TeSADH. 
 
 
 
 
 
 
96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A20. GC chromatogram and MS spectrum of the (R)-2d prepared by W110G 
TeSADH. 
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Figure A21. GC chromatogram and MS spectrum of the (S)-2e prepared by W110G 
TeSADH. 
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Figure A22. MS spectrum of the (R)-2l prepared by W110A/I86A TeSADH . 
 
 
 
Figure A23. GC spectrum of the (R) -2o prepared by W110A/I86A TeSADH. 
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Figure A24. MS spectrum of the (R)-2q prepared by W110A/I86A TeSADH . 
 
 
 
Figure A25.  MS spectrum of the 2r prepared by W110A/I86A TeSADH . 
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. Figure A26. MS spectrum of the (R)-2s prepared by W110A/I86A TeSADH.  
 
 
Figure A27. MS spectrum of the (R)-2v prepared by W110A/I86A TeSADH.  
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3. NMR spectra 
 
 
 
Figure A28. 1H NMR spectrum of the (S)-2a prepared by W110G TeSADH. 
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Figure A29. 13C NMR spectrum of the (S)-2a prepared by W110G TeSADH.  
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Figure A30. 1H NMR spectrum of the (R)-2b prepared by W110G TeSADH.  
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Figure A31. 13C NMR spectrum of the (R)-2b prepared by W110G TeSADH.  
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Figure A32. 1H NMR spectrum of the (S)-2c prepared by W110G TeSADH.  
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Figure A33. 13C NMR spectrum of the (S)-2c prepared by W110G TeSADH.  
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Figure A34. 1H NMR spectrum of the (R)-2d prepared by W110G TeSADH.  
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Figure A35. 13C NMR spectrum of the (R)-2d prepared by W110G TeSADH.  
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Figure 36. 1H NMR spectrum of the (S)-2e prepared by W110G TeSADH.  
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Figure A37. 13C NMR spectrum of the (S)-2e prepared by W110G TeSADH.  
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Figure A38. 1H NMR spectrum of the (R)-2l prepared by W110A/I86A TeSADH.  
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Figure A39. 13C NMR spectrum of the (R)-2l prepared by W110A/I86A TeSADH.  
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Figure A40. 1H NMR spectrum of the (R) -2o prepared by W110A/I86A TeSADH.  
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Figure A41.13C NMR spectrum of the (R) -2o prepared by W110A/I86A TeSADH.  
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Figure A42. 1H NMR spectrum of the (R) – 2q prepared by W110A/I86A TeSADH.  
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Figure A43. 13C NMR spectrum of the (R) -2qprepared by W110A/I86A TeSADH.  
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Figure A44. 1H NMR spectrum of the 2r prepared by W110A/I86A TeSADH.  
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Figure A45. 13C NMR spectrum of the 2r prepared by W110A/I86A TeSADH.  
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Figure A46. 1H NMR spectrum of the (R) -2s prepared by W110A/I86A TeSADH.  
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Figure A47. 13C NMR spectrum of the (R) – 2s prepared by W110A/I86A TeSADH.  
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Figure A48. 1H NMR spectrum of the (R) – 2v prepared by W110V TeSADH.  
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Figure A49. 13C NMR spectrum of the (R) – 2v prepared by W110V TeSADH.  
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4. FT-IR spectra 
 
 
 
Figure A50. FT-IR spectrum of the (S)-2a prepared by W110G TeSADH.  
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Figure A52. FT-IR spectrum of the (R)-2b prepared by W110G TeSADH.  
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Figure A53. FT-IR spectrum of the (S)-2c prepared by W110G TeSADH.  
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Figure A54. FT-IR spectrum of the (R)-2d prepared by W110G TeSADH.  
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Figure A55. FT-IR spectrum of the (S)-2e prepared by W110G TeSADH.  
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Figure A56. FT-IR spectrum of the (R) –2l prepared by W110A/I86A TeSADH.  
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Figure A57. FT-IR spectrum of the (R)-2o prepared by W110A/I86A TeSADH.  
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Figure A58. FT-IR spectrum of the (R) – 2q prepared by W110A/I86A TeSADH.  
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Figure A59. FT-IR spectrum of the 2r prepared by W110A/I86A TeSADH.  
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Figure A60. FT-IR spectrum of the (R) –2s prepared by W110A/I86A TeSADH.  
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Figure A61. FT-IR spectrum of the (R) -2v prepared by W110V TeSADH.  
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